Ma, Henry, Campbell, Bruce C. V., Miteff, Ferdinand, Tsai, Chon-Haw, Lee, Jiunn-Tay, Phan, Thanh G., Mahant, Neil, Sun, Mu-Chien, Krause, Martin, Sturm, Jonathan, Grimley, Rohan, Chen, Chih-Hung, Parsons, Mark W., Hu, Chaur-Jong, Wong, AA, Field, D, Sun, Y, Barber, PA, Sabet, A, Jannes, J, Jeng, JS, Clissold, B, Markus, R, Churilov, Leonid, Lin, CH, Lien, LM, Bladin, CF, Christensen, S, Yassi, N, Sharma, G, Bivard, A, Desmond, PM, Yan, B, Mitchell, PJ, Levi, Christopher R., Thijs, V, Carey, L, Meretoja, A, Davis, SM, Donnan, GA, Hsu, Chung, Kleinig, Timothy J., Wijeratne, Tissa, Curtze, Sami, Dewey, Helen M.. Massachusetts Medical Society; 2019. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke.

Meretoja, Atte, Yassi, Nawaf, Wu, Teddy Y., Churilov, Leonid, Sibolt, Gerli, Jeng, Jiann-Shing, Kleinig, Timothy, Spratt, Neil J., Thijs, Vincent, Wijeratne, Tissa, Cho, Der-Yang, Shah, Darshan, Cloud, Geoffrey C., Phan, Thanh, Bladin, Christopher, Moey, Andrew, Aviv, Richard I., Barras, Christen D., Sharma, Gagan, Hsu, Chung Y., Levi, Christopher, Ma, Henry, Campbell, BCV, Mitchell, P, Yan, B, Parsons, MW, Tiainen, M, Curtze, S, Strbian, D, Tang, SC, Harvey, J, Donnan, GA, Davis, SM. The Lancet Publishing Group; 2020. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.

Yassi, Nawaf, Zhao, Henry, Jeng, Jiann-Shing, Choi, Philip M. C., Duc, Phuc Dang, Brown, Helen, Ranta, Annemarei, Spratt, Neil, Cloud, Geoffrey C., Wang, Hao-Kuang, Grimley, Rohan, Mahawish, Karim, Churilov, Leonid, Cho, Der-Yang, Shah, D, Nguyen, TMP, Sharma, G, Yogendrakumar, V, Yan, B, Harrison, EL, Devlin, M, Cordato, D, Martinez-Majander, N, Wu, Teddy Y., Strbian, D, Thijs, V, Sanders, LM, Anderson, D, Parsons, MW, Campbell, BCV, Donnan, GA, Davis, SM, Ma, Henry, Nguyen, Huy-Thang, Cheung, Andrew, Meretoja, Atte, Mai, Duy Ton, Kleinig, Timothy. The Lancet Publishing Group; 2024. Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial.